BEIJING, April 17, 2019 /PRNewswire/ — In April 2019, the famous breast disease expert in China, Dr. Du Yutang, and his doctor’s team officially joined Beijing Sanfine International Hospital. The partners plan to develop the diagnosis and treatment center for GLM (Granulomatous Lobular Mastitis) and post-plastic surgery center.

Professor Du Yutang has contributed his entire life to advancing clinical practice and the study of breast diseases (ICD-10-CM: N60-N65)

After working for more than 50 years in clinical practice, now – almost 80 years old – Professor Du, has diagnosed and treated tens of thousands of patients suffering from mammary diseases in China and patients from abroad. The patients warmly refer to him as, “Grandpa Du”. After his retirement, Professor Du has utilized his time for research and knowledge sharing, devoting a majority of his efforts on Periductal Mastitis (PDM) and Granulomatous Lobular Mastitis (GLM), which are difficult to detect, diagnose, and treat.

His resolute attitude and passion for breast disease research compounds from the patients who Dr. Du has treated over his years of experience. Dr. Du and his team are confident in their contributions to breast cancer treatments, breast complication diagnoses, and intractable breast diseases. However, what continues and has long made them deeply distressed is the suffering GLM patients endure: the repeated recurrences, sharp pain, festering, ulceration, and long-term non-healing.

GLM was first defined as a disease in 1972. At that time, it happened mainly in Egypt, Turkey, and other Mediterranean coast countries, which still hold high morbidity. Most of the symptoms were considered as cancer, but the pathology analysis showed that it is not cancer. However, although it is not fatal, it causes the pain no less than that of breast cancer. It is imperative to pay more attention to the increasing morbidity of GLM in China, which has increased exponentially over the last decade. Yet, because this disease is not well known, misdiagnosis is very common.

Professor Du’s surgical invention of ‘Smear Detection and Removal’ has successfully saved breasts and has been recognized as the most viable treatment for PDM and GLM. This has earned him renown as the foremost expert in the GLM field. Today, the number and complexity of cases treated by his team have reached the top in the breast disease field.

The cause analysis of GLM（Granulomatous Lobular Mastitis）

Professor Du believes that the basis for the onset of GLM is milk deposition or retention in the milk duct. That is why it is more common in the 6 years following child delivery. However, postpartum breast milk stasis after delivery is a physiological phenomenon. It is difficult to explain why there were no occurrences of GLM in China, Africa, and Russia decades ago. It is also difficult to explain the lower morbidity of GLM in Caucasians and Japanese. Therefore, there must be another cause of GLM, but it is still unknown. Etiology research is difficult to conduct for clinicians, so they have to analyze from inducements or the factors that stimulate the onset of GLM.

According to Professor Du’s analysis of 532 cases in 2018, breastfeeding disorders, blunt trauma, food contaminants and unhealthy diet habits, lactation during pregnancy, medical abortion, drug-induced granuloma (such as taking various contraceptives) and, local or systemic prolactin (PRL) elevation, are all important factors that have been observed to trigger GLM. Therefore, for GLM patients, Professor Du regularly suggests checking six sex hormones before surgery and tracking changes in PRL.

Devoting equal attention to state-of-the-art technology and top-notch patient care, Professor Du chooses Sanfine

The high probability of misdiagnosis of this kind of breast disease leads to a high frequency of mistreatment. By the time patients from all over the world find Professor Du, they have already experienced a long process of detours and thus entered the later stage of the disease, a miserable situation.

The Du YuTang Mammary Doctors Group has chosen Beijing Sanfine International Hospital, based on the consideration for characteristics of GLM, and the needs of post-op plastic surgery and psychological rehabilitation. Beijing Sanfine International Hospital is known for its patient-centered care, and its successful implementation of the International PHP Model (Physician Hospital Partnership) since its establishment three years ago. Since the beginning, Beijing Sanfine International Hospital has paid great attention to creating a series of support systems for doctors’ medical treatment, including international standard management procedures, medical quality control, impeccable equipment, comprehensive departmental services, and a patient-centered medical service environment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-famous-breast-disease-expert-in-china-dr-du-yutang-is-committed-to-establishing-a-diagnosis-and-treatment-center-for-glm-in-beijing-sanfine-international-hospital-300833724.html

NEW YORK and LONDON, April 18, 2019 /PRNewswire/ — TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3).  TAU BIO-LOGIC is developing TBL-100 for the treatment of Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP). The humanized antibody has an affinity for tauC3 of 13pM (about 100-fold higher than most marketed therapeutic antibodies have for their targets) and a specificity that is 1000-fold greater than for full length tau (FLT).  The high affinity and specificity of the antibody are expected to translate into improved efficacy and safety compared to other tau antibodies currently in development. TauC3 exists in lower abundance than FLT or N-terminally truncated tau but exerts disproportionately large pathological effects.  This is due to tauC3 having the highest propensity to aggregate among all forms of tau and its also having the ability to recruit normal tau and nucleate pathological tau conformations.  In AD, tauC3 is formed early in the disease course and levels correlate with cognitive decline. TauC3 causes intracellular neurotoxicity and is also believed to be the major driver of tau propagation. A study conducted by Professor Bradley Hyman at Harvard Medical School demonstrated TBL-100’s  potential to block tau propagation in the AD brain (Nicholls et al., 2017; PLoS ONE 12(5): e0177914). In PSP, tauC3 production and activity have been linked to a single polynuclear polymorphism (SNP) at rs1768208, a significant risk factor for the disease.  Thus, TBL-100 could be beneficial for this condition as well.

The humanization of TBL-100 was conducted by LifeArc under a risk sharing agreement with TAU BIO-LOGIC, with terms that would see LifeArc receive a small royalty on future drug sales.  “We are delighted to have contributed to the development of TBL-100, ” said Dr Justin Bryans, head of  LifeArc’s Centre for Therapeutic Discovery. “The collaboration has produced a lead candidate for further development and several good backup molecules offering a combination of excellent biophysical characteristics and thermostability properties, high affinity binding and high expression.

“Successful humanization marks an important milestone in the development of TBL-100, which we believe offers several advantages compared to other anti-tau antibodies and small molecule tau treatments in development, both in terms of safety and improved efficacy,” said Daniel G. Chain, PhD, President and CEO of TAU BIO-LOGIC.  “We aim to rapidly advance this promising disease-modifying therapeutic agent for patients suffering from AD and PSP since these conditions currently lack effective therapies.

About TAU BIO-LOGIC CORPORATION
TAU BIO-LOGIC is a privately held biopharmaceutical company focused on the development of innovative high precision immunotherapies for the treatment of Alzheimer’s disease (AD), Supranuclear Palsy (PSP) and related neurodegenerative conditions. The company’s lead product is TBL-100 a monoclonal antibody that binds and inhibits the activity of C-terminally truncated tau (tauC3).   The humanized antibody has an affinity of 13pM  (about 100-fold higher than most marketed therapeutic antibodies have for their targets) and a specificity that is 1000-fold greater than for full length tau (FLT).  The high affinity and specificity of the antibody are expected to translate into improved efficacy and safety compared to other tau antibodies currently in development.

About LifeArc
LifeArc is a medical research charity with a 25-year legacy of helping scientists and organizations translate their research into treatments and diagnostics for patients. LifeArc turns great science into greater patient impact. The charity brings together a network of partners to tackle specific diseases and directly funds academic and early stage research. So far, LifeArc’s work has helped to develop four approved medicines (Keytruda^®, Actemra^®, Tysabri^® and Entyvio^®) and a diagnostic test for resistance to carbapenem.

About AD
AD is the most common cause of dementia and represents an enormous and growing global public health challenge.  It is a uniformly fatal neurodegenerative disorder with no cure or substantially effective treatment. AD currently affects more than 5 million Americans, 7 million Europeans and, in total, about 44 million people worldwide according to the most recent report by the Alzheimer’s Association. No disease-modifying treatments have been approved for either the early or late disease stages.

About PSP
PSP is a rare and fatal degenerative neurological disorder affecting about 20,000 people in the United States.  It causes progressive impairment of balance and walking; impaired eye movement, abnormal muscle tone, speech difficulties, and problems related to swallowing and eating. Affected individuals also frequently experience personality changes and cognitive impairment.  Symptoms typically begin after age 60 but can begin earlier. The exact cause of PSP is unknown, and the disease is often initially misdiagnosed as Parkinson’s disease. No disease-modifying treatments have been approved for either the early or late disease stages.

Contacts:

Daniel G. Chain, PhD, President & CEO, TAU-BIOLOGIC; dchain@taubiologic.com
Paul Brennan, VP Business Development, TAU-BIOLOGIC; pbrennan@taubiologic.com 

Logo – https://mma.prnewswire.com/media/873067/TBL_Logo.jpg

Frost & Sullivan Transformational Health expert leads a webinar on a simple model for assessing your own community’s strength relative to the healthcare technology and biosciences market

SANTA CLARA, Calif., April 17, 2019 /PRNewswire/ — For most cities and states, the healthcare technology and biosciences sector are two of the most attractive industries of the future that can grow their communities. However, that attention attracts significant competition among players seeking to expand in a field that is highly complex. How should your community address this industry, and what is the best path to nurturing start-ups, retaining existing employers, attracting new companies and encouraging workforce development?

Discover the Best Strategies for Innovation at the Community Level for Healthcare Technology and Biosciences

Frost & Sullivan invites you to join our Transformational Health expert, Charlie Whelan, for the webinar “Growth Opportunities in the Healthcare Technology and Biosciences Sector”, on Tuesday, May 14, 2019, from 11:00 AM to 12:00 PM Eastern Time and gain insight into opportunities in the healthcare technology and biosciences sector, along with recommendations for communities to consider and develop a successful strategy.

For more information and to register for the webinar, please visit: http://frost.ly/3dv.

“The strategy for any community’s success in healthcare technology and biosciences must build on its own unique set of assets and capabilities. Don’t expect to be Silicon Valley, Boston or Minneapolis. At the same time, there is evidence of what kinds of programs are most effective. In such a large, fast growing and innovative field, there is plenty of room for growth for everyone,” explains Whelan.

Key benefits of attending this webinar:

• The healthcare technology and biosciences market is large and complex. Learn how the industry is structured and which segments might align best with your community.
• Cities and states across the country are all competing to grow their own biosciences economies. Find out what types of programs and strategies are the most effective.
• Come away with a simple model for assessing your own community’s strength relative to the healthcare technology and biosciences market.

The event will also be recorded and available for on-demand viewing at http://frost.ly/1ti. 

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Press Contact: 

Mariana Fernandez
Frost & Sullivan     
+1 (210) 348 1012
mariana.fernandez@frost.com

Photo – https://mma.prnewswire.com/media/873339/Frost_and_Sullivan_Health_Webinar.jpg

Collaborative Medicinal Development LLC (CMD), announces that it was awarded a AU$1 million grant from FightMND to support a Phase 2 study of CuATSM for treatment ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease, or Motor Neuron Disease (MND).

MILL VALLEY, California and MELBOURNE, Australia, April 18, 2019 /PRNewswire/ —

The Background

In 2016, FightMND helped to support the phase 1 clinical trial of CuATSM where it was given to MND patients as a therapeutic for the first time. The primary objective, as per any phase 1 trial, was to assess safety and tolerability of the drug and, if possible, identify a dose that could be taken to the next round of testing.  By assessing the drug at a number of different doses the trial successfully identified a recommended dose for phase 2 testing.  Although a Phase 1 study is not designed to prove efficacy, signals of disease modification were demonstrated.  Accrual to the Phase 1 study is now completed.

The Plan

The next step in development is to perform a randomized, double blind, placebo controlled study.  “With FightMND’s generous second grant, the Phase 2 study will start later in 2019” said Dr. Craig Rosenfeld, the CEO of CMD.  Phase 2 study details will be posted on https://clinicaltrials.gov/ in the next few months.

CMD’s goal is to advance a disease modifying therapy for ALS and to have CuATSM approved by the FDA.

FightMND

“FightMND is dedicated to finding an effective treatment or cure for MND, also referred to as ALS or Lou Gehrig’s disease,” said Rebecca Sheean, Ph.D., Research Manager of FightMND.  “FightMND’s support for CMD to perform a Phase 2 study of CuATSM is consistent with our goals. We are excited that our support for CMD has allowed CuATSM to advance towards this next phase of clinical testing and hopefully towards a disease modifying therapeutic for patients with ALS.”

About CuATSM

CuATSM is a once daily oral medication.  The effectiveness of CuATSM was replicated in four mouse models of ALS.  Further, the therapeutic potential of CuATSM in ALS was corroborated at three independent sites.

About Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive and fatal neurodegenerative disease characterized by muscle weakness resulting from degeneration of motor neurons. Patients usually die of respiratory failure within 2 to 3 years of symptoms onset.  There is an urgent unmet medical need for disease-modifying therapies in ALS.  Further information about ALS is available at https://fightmnd.com/

About Collaborative Medicinal Development LLC

CMD is a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases.  The Company’s lead drug, CuATSM, was licensed from the University of Melbourne and entered clinical trials in ALS and Parkinson’s disease in 2017. The CMD team includes Craig Rosenfeld, MD (CEO), Kay Noel, PhD (COO), and Jim Babcock (Chairman, founder of Cthulhu Ventures LLC, CMD’s founding investor). For more information about CMD, visit the website at https://colmeddev.com/.

Contact Information
For further Information
Rory Hill, Business Development
RoryH@colmeddev.com

Logo – https://mma.prnewswire.com/media/805027/CMD_Logo.jpg  

YONGIN, South Korea, April 16, 2019 /PRNewswire/ — GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, joins World Hemophilia Day, observed annually by the World Federation of Hemophilia (WFH) and the global hemophilia community to raise awareness of the disease and other bleeding disorders. This year’s slogan is “Reaching out: The First Step to Care”. With this slogan, the global bleeding disorder’s community focuses on the the importance of improving interest and awareness of hemophilia.

As part of GC Pharma’s continued support of the hemophilia community, the company features this year’s slogan image on its global website and giant exterior façade of its main campus in Yongin, South Korea.

“GC Pharma is proud to support the global hemophilia community in honouring World Hemophilia Day,” said EC Huh, Ph. D., president of GC Pharma. “We will also strive to develop innovative drugs to make a difference in the lives of people with bleeding disorders.”

World Hemophilia Day (WHD) occurs each year on April 17. Since its creation in 1989, WHD has served as an opportunity to increase awareness of hemophilia and other bleeding disorders.

About Hemophilia

Hemophilia is a congenital disorder that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood. Hemophilia A is more common than hemophilia B; hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide. Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding. People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.

About GC Pharma

GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand to GC Pharma in early 2018. Green Cross Corporation remains the company’s registered, legal name.

View original content to download multimedia:http://www.prnewswire.com/news-releases/gc-pharma-marks-world-hemophilia-day-300832513.html

SHANGHAI, April 15, 2019 /PRNewswire/ — The 15^th Exhibition of Medical Device Design & Manufacturing in China (Medtec China 2019) will take place from September 25-27, 2019, at Shanghai World EXPO Exhibition & Convention Center, and the co-located conference — MDiT Forum and Regulation Summit 2019 will be also held at the same time, providing valuable learning opportunities for industry insiders and propelling the development of the medical device industry. The focus of the MDiT Forum and Regulation Summit 2019 remains on Regulation, Quality and Technology and renowned speakers will be invited to present compelling topics to attendees.

Regulation Track: Chinese Regulatory Updates and Compliance

Regulation Track aims to provide interpretations on the latest medical regulations and standards in China. What are the implications of regulation updates in 2018 for the medical device industry, and what are the opportunities and challenges for device manufacturers? The answers will be found on site. Experts will also interpret the reform of the Medical Device Clinical Trial Management System, including changes with the catalog of medical devices exempted from clinical trials, and changes in clinical trial requirements for different categories of medical devices.

Regulation Track Chinese Regulatory Updates and Compliance 2018

Quality Track: “Risk Management of Medical Product Life Cycle” and “MDSAP updates and FDA Inspection”

At Quality Track A: “Total Lifecycle Risk Management for Medical Products”, experts will initiate specific discussions on risk management-oriented biological evaluation and testing, risk management in medical device product design and development, how to implement total lifecycle risk management against regulatory inspections upon product launch, and other topics.

Medical device manufacturers that are about to or expected to enter the US market will acquire at the Quality Track B: “Latest MDSAP Developments and FDA Factory Inspection” effective practical experience and case analysis of FDA factory inspection and of using QSIT technology to facilitate FDA on-site inspection.

Technology Track: The 7^th IIMD China Summit (Implantable and Interventional Medical Device)

IIMD China Summit featured with IIMD exhibits and exhibitors at Medtec China 2019, will initiate discussions on IIMD regulations, market trends, design and material innovation centering on orthopedic implants, cardiovascular intervention products and 3D printing products. Such topics will certainly benefit those who attend the summit.

Other cannot-miss free activities

In addition, there will be a series of high-quality conferences and events free-of-charge, with themes covering medical materials, plastic molding, medical design, electronics, sterilization & packaging, international regulations, and market analysis. Topics will include R&D and technology sharing of transparent film medical dressing, the practical application of flat hot runner technology in medical device manufacturing, updates with ethylene oxide sterilization, the latest R&D of pacemakers and the demand for its core components, and how medical device manufacturers should prepare for MDR and IVDR certifications, The activities aim to explore the application of new technologies under the new situation, and to strengthen upstream and downstream collaboration. Click here to review 2018 conference content.

The 4th Market Report Track of Medical Device Industry

Medtec China will be held in Shanghai from September 25-27, 2019. Upon its 15th anniversary since it was first held, Medtec China will gather more than 450 leading exhibitors, including DuPont, Mikron, Eastman, Clariant, DSM, Hitachi, Branson, Marposs, and Ourway Packaging, to provide leading medical devices, materials and technology solutions for global buyers. It is expected to attract more than 250,000 visitors who come for business negotiations, procurement and technological exchanges. Visitor pre-registration is coming soon at the end of the month. For more information, please visit: www.medtecchina.com

Exhibit, visit or media cooperation, please contact：
Carina Li
Tel.: +86 10 5730 6163
E-Mail: carina.li@ubm.com  
Medtec China Organization Committee

Photo – https://photos.prnasia.com/prnh/20190411/2433429-1-a
Photo – https://photos.prnasia.com/prnh/20190411/2433429-1-b

SUNDSVALL, Sweden, April 15, 2019 /PRNewswire/ — Permobil, a global leader in advanced rehabilitation technology, has updated its successful modular front wheel drive chair with new functions for improved body support and comfort, more flexible body positioning and smoother driving, as well as updated styling that lets users personalize their chairs. The new F-Series, unveiled at the International Seating Symposium in Pittsburgh, U.S. on March 19, will be officially launched in Japan at the Osaka Barrier Free Exhibition 2019 (April 18-20).

DJ Muto, a popular DJ in Japan, uses an F5 Corpus VS to prepare his shows

Since 1967, Permobil’s technology has enhanced freedom of movement for people with disabilities and enabled them to fully participate in society, a pressing topic in Japan ahead of the Olympics and Paralympics in 2020. The new F-Series is no exception, incorporating a slew of innovations:

• Updated Corpus seating system and cushions improve immersion into the seat for increased comfort and stability.
• Active Height seat elevator gives the user independence to reach, enables eye-to-eye contact and elevated driving at walking speed.
• Agile suspension offers independent suspension of all four wheels. This is beneficial when driving outdoors or for users with alternative drive control devices. Optional front- and rear-LED lights that are twice as bright as before ensure safe driving in dark conditions.
• Actuators have been doubled in strength to allow users up to 150kg to use the power recline function, enabling movement and body positioning to prevent secondary complications.
• A range of 13 easily interchangeable color decals, along with updated styling, enables users to personalize their chair to express themselves.

“The new F-series has been specifically designed to address the medical, functional and social needs of the user. We are proud to be able to offer it in Japan, which is an important growth market for Permobil. Alongside power functions such as Active Reach, we are delighted to offer users updated aesthetics and an expanded color palette. Looking good is of course hugely important to people who sit in a wheelchair all day every day,” says Chuji Kaseda, Managing Director, Permobil K.K. 

Linda Nilsson, Global Product Marketing Manager, adds, “The new F-series not only updates the look of the chair. Upgrades to the engineering side means an increase to the drive speed while the seat is in an elevated position to 5km/h, close to walking speed.”

The F-series has three models: the F3 Corpus with its compact footprint and tight turning radius makes it ideal for indoor and occasional outdoor use; F5 Corpus is a perfect hybrid for indoor and outdoor use and active lifestyles; and the F5 Corpus VS offers the same as the F5 Corpus with the added benefit of a standing functionality.

The modular chassis is a four-wheel power wheelchair with the drive wheels positioned towards the front seating system, in order to allow for excellent indoor and outdoor performance and maneuverability.  

For more information:

ENTER LOCAL CONTACT INFORMATION

Martinus Ronnerman, Director Group Communications, Permobil / +46 702 63 68 05 / martinus.ronnerman@permobil.com  

About Permobil

Permobil founder Dr. Per Udden believed that helping people achieve the greatest level of independence is a basic human right and, for over 50 years, Permobil has held fast to that belief. Permobil is a global leader in advanced rehabilitation technology, passionate about better understanding our users’ needs and improving their quality of life through state-of-the-art healthcare solutions. Today, those solutions include power wheelchairs, seating and positioning products, power assist, and manual wheelchairs. Permobil is part of Patricia Industries, a subsidiary of Investor AB and is headquartered in Sweden. Permobil has 1600 team members in more than 15 countries around the world. For more information regarding the company’s storied history and complete product line visit permobil.com. 

Photo – https://photos.prnasia.com/prnh/20190411/2427077-1

SHANGHAI, April 11, 2019 /PRNewswire/ — I-Mab Biopharma (“I-Mab”), a clinical stage biopharmaceutical company exclusively focused on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases enters into a collaboration with Roche for I-Mab’s clinical study to evaluate TJD5 in combination with atezolizumab (TECENTRIQ^®).

Roche will supply atezolizumab (TECENTRIQ^®) to I-Mab for use in clinical study in combination with TJD5. All rights generated in the study will belong jointly to I-Mab and Roche.

TJD5 is a proprietary innovative CD73 antibody from I-Mab’s discovery pipeline with best-in-class potential. CD73 is an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which contributes to a highly immunosuppressive tumor micro-environment. On January 18, 2019, TJD5 received IND clearance from the U.S. FDA. 

Dr. Joan Shen, Head of R&D of I-Mab, commented, “We are thrilled to collaborate with Roche, a global leader of cancer immunotherapy, and we look forward to maximizing the potential of TJD5 to meet the clinical needs all over the world.”

About TJD5:
TJD5 is a differentiated monoclonal antibody against another promising immuno-oncology target, CD73. It is expected to stimulate the immuno-suppressive tumor micro-environment and to work in concert with other cancer therapies such as PD-1 and PD-L1 antibodies. TJD5 acts through a unique intra-dimerization mechanism for anti-cancer activities and inhibit the target enzyme activity completely. This unique mechanism of action ensures the molecule to work normally without a “hook effect” as evident in our preclinical studies.

About I-Mab:
I-Mab is a dynamic and fast-growing China-based global player exclusively focused on developing potential first-in-class and/or best-in-class biologics in the areas of immuno-oncology and autoimmune diseases through internal R&D capabilities and global partnerships. I-Mab’s pipeline is driven by the company’s development strategy to address unmet needs in China and to bring innovative assets to the world. The company is prepared to submit additional INDs in order to initiate clinical trials in China and the U.S., including multiple Phase 2 and Phase 3 studies. I-Mab is on a fast track toward becoming an end-to-end fully integrated biopharma company. The company has been well-recognized by capital markets by successfully raising approximately USD 370 million within 12 months, with its USD 220 million Series C financing in July, 2018, representing one of the largest amounts ever raised by an innovative biotech company in China. 
www.i-mabbiopharma.com

Company contact: 

Investor contact:
Jielun Zhu
CFO
jielun.zhu@i-mabbiopharma.com

Business Development contact:
Yunfei Zhang
Director, Global Business Development
yunfei.zhang@i-mabbiopharma.com 

Media contact:
Amanda Dai
+86-18116260519
Associate Director of Public Relation
zhenhua.dai@i-mabbiopharma.com

View original content:http://www.prnewswire.com/news-releases/i-mab-biopharma-signs-agreement-for-clinical-research-of-tjd5-in-combination-therapy-300829878.html

SHANGHAI, April 11, 2019 /PRNewswire/ — China’s leading one-stop healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited (“Ping An Good Doctor“, or the “Company”, stock code: 1833.HK) has announced that it has stationed a “One-minute Clinic” at Shanghai Jiao Tong University, to safeguard the health of all teachers and students with its world-leading artificial intelligence (AI) technology. This is another new offline service scenario developed by Ping An Good Doctor following the launch of One-minute Clinics across enterprises, large communities, chain pharmacies and expressway service areas in China.

Ping An Good Doctor Launches “One-Minute Clinic” at Shanghai Jiao Tong University

As the first unmanned clinics currently in commercial operation in China, One-minute Clinics utilize Ping An Good Doctor’s world-leading mobile healthcare and AI technology, and integrate a variety of smart medical examination devices, connecting with more than 1,000 in-house medical personals and nearly 5,000 renowned external contracted doctors. The clinics provide users with one-stop medical and healthcare services, including consultation, rehabilitation guidance, medication recommendation, and medicine. Every One-minute Clinic has more than 100 categories of common drugs, all of which are cryogenically refrigerated to ensure their quality. 

The One-minute Clinic at Shanghai Jiao Tong University provides teachers and students with an alternative option to the medical clinics on campus. AI Doctor, Ping An Good Doctor’s world leading technology, plays a key role. AI Doctor was developed by the R&D team with over 200 world-class AI experts and has accumulated more than 400 million pieces of consultation records. When patients use the consultation service in One-minute Clinics, AI Doctor acts like a real doctor and collects information on the users’ symptoms and illness history before providing a preliminary diagnostic suggestion. The experienced real doctor then joins the consultation with supplementary recommendations to ensure the accuracy of the whole consultation process.

Upon the launch, Zhao, a student at Shanghai Jiao Tong University who used the One-minute Clinic, said it is very convenient that the clinic is located inside a school building, making it easy to purchase emergency medical supplies like medical tapes. He visited the One-minute Clinic while suffering from a stomachache. After an in-depth inquiry about his symptoms, drug allergy history and other relevant information, the AI Doctor and online doctor provided relevant medical advice, and Zhao’s stomachache was quickly relieved after purchasing and taking medicines from the medicine cabinet next to the clinic.

Ping An Good Doctor spokesperson said that in response to young students and campus employees’ needs, the One-minute Clinic prescribes drugs that are relevant to the daily habits of people on the campus, such as eye drops, antidiarrheal drugs, Band-Aids and other common drugs for students, and menthol pills and pharyngitis tablets for teachers. The One-minute Clinic helps to improve the health of students and teachers, preventing diseases, which improves their work efficiency and urges students to develop a healthy lifestyle.

At present, the One-minute Clinics provide a variety of different offline service scenarios in China, covering the needs of residents, tourists, drivers, students and teachers. In the near future, it will be launched in more public areas, including shopping malls, airports, and train stations, which will complete the medical service circle in the city.

Photo – https://photos.prnasia.com/prnh/20190411/2433585-1

WUHAN, China, April 12, 2019 /PRNewswire/ — Wuhan, capital city of central China’s Hubei province, has attracted ten major healthcare industry companies, including Taikang Group and China Biotech, to participate in building its Health Industrial Park.

The Health Industrial Park is being created with the goal of becoming a 100 billion yuan (about 15 billion U.S. dollars) hotspot of biomedicine, medical equipment, and healthcare by 2030, according to a local official at the ongoing First World Health Expo.

Wuhan’s Jiangxia District, known as China Guanggu, or China’s “Optics Valley,” has formed a health-centered industrial cluster of bio-pharmaceutical, diagnostic equipment, and drug manufacturers. The planned Guanggu Health Industrial Park will cover 98.1 square kilometers.

Compared with Wuhan Guanggu Bio-City, which brings in revenue in excess of 100 billion yuan, the park will focus on the research and development of cutting-edge technologies in the fields of life and health while incubating key healthcare enterprises.

The Health Industry Park is positioned as a “production-research interaction” space which integrates R&D and manufacturing activities in harmony. The park will partner with Guanggu Bio-City to facilitate active industrial collaboration.

Jiangxia District will offer a preferential policy support package to health industry enterprises interested in the area, which will include financial services and R&D incentives.

Zhang Li, Jiangxia District mayor, said that Optics Valley Nanda Health Industrial Park would provide preferential policies and financial support to enterprises interested in the area. The value of a single-item policy fund is over 100 million yuan, or around 15 million U.S. dollars.

The Wuhan Health Industry Development Plan specifies that Guanggu Nanda Health Industry Park intends to introduce 100 enterprises over the next 10 years in building a 100 billion yuan-level center of business. 50,000 employees are projected to participate in establishing the fifth national industrial park in Wuhan, reaching an important milestone for Wuhan’s healthcare industry.

View original content to download multimedia:http://www.prnewswire.com/news-releases/wuhan-lays-out-construction-of-guanggu-nanda-health-industrial-park-300831254.html